KCA
Search
- Page Path
- HOME > Search
Original Article
- Breast cancer
- Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
- Yong-Pyo Lee, Min-Sang Lee, HongSik Kim, Ji-Yeon Kim, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
- Cancer Res Treat. 2022;54(4):1130-1137. Published online January 17, 2022
- DOI: https://doi.org/10.4143/crt.2021.1103
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
Trastuzumab has markedly improved the survival outcomes of patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer, and dual blockade of HER2 using trastuzumab and pertuzumab in combination with taxanes (THP) has become a standard of care for HER2-positive metastatic breast cancer (MBC) worldwide since the CLEOPATRA trial. We assessed the outcomes of THP as a first-line treatment for Korean HER2-positive MBC patients in the real-world setting.
Materials and Methods
Between August 2008 and October 2020, we identified 228 HER2-positive MBC patients who received THP as a first-line palliative chemotherapy. We analyzed survival outcomes, efficacy, and adverse events of THP retrospectively.
Results
After a median follow-up duration of 28.7 months, median overall survival and progression-free survival were 58.3 months (95% confidence interval [CI], 36.6 to 80.0) and 19.1 months (95% CI, 16.2 to 21.9), respectively. Better survival outcomes were observed in patient who received docetaxel for more than six cycles. Patients exposed to anti-HER2 directed therapies in a perioperative setting had poor survival outcomes. The overall response rate was 86.8% with a complete response (CR) rate of 17.7%. Among responders, 16.7% of patients sustained THP over 35 months and showed better survivals and higher CR rates. Adverse events were comparable to those reported in previous studies.
Conclusion
In a real-world context, clinical outcomes of Korean HER2-positive MBC patients treated with THP were similar to those of patients in the CLEOPATRA trial. Much longer follow-up results would be warranted. -
Citations
Citations to this article as recorded by
- Trastuzumab deruxtecan: Redefining precision oncology across HER2-driven cancers
Pooya Jalali, Azhar Saeed, Sahar Taher, Anwaar Saeed
Critical Reviews in Oncology/Hematology.2026; 217: 105019. CrossRef - From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching
Mariangela Gaudio, Anna Floreani, Greta Schivardi, Domiziana Alaimo, Vera Basilico, Isabella Lorenzetti, Cristina Crepaldi, Benedetta Tinterri, Antonella Panzardi, Daniela Strada, Giuseppe Saltalamacchia, Flavia Jacobs, Chiara Benvenuti, Riccardo Gerosa,
Tumori Journal.2026; 112(1): 22. CrossRef - Pertuzumab–Docetaxel–Trastuzumab regimen in HER2-positive metastatic breast cancer: Real-world data from India
Ajay Gogia, Atul Batra, Ashutosh Mishra, Kamal Kataria, Surendra K Saini, Sandeep Mathur, Chandra P Prasad, Hari Krishna Raju Sagiraju
Cancer Treatment and Research Communications.2026; 47: 101196. CrossRef - Translating CLEOPATRA into routine practice: National treatment patterns and survival for patients with HER2-positive metastatic breast cancer
Kathrine F. Vandraas, Sarah Hjorth, Cassia B. Trewin-Nybråten, Bettina K. Andreassen, Egil S. Blix, Bjørn Naume, Edoardo Botteri, Giske Ursin, Nathalie C. Støer
The Breast.2026; 89: 104852. CrossRef - Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review
Ignacio Ventura, Nerea Pinilla Salcedo, Marcelino Pérez-Bermejo, Javier Pérez-Murillo, Manuel Tejeda-Adell, Francisco Tomás-Aguirre, María Ester Legidos-García, María Teresa Murillo-Llorente
International Journal of Molecular Sciences.2025; 26(5): 1908. CrossRef - Recent advances in immunotherapy for breast cancer
Yi Guo, Gang Zheng, Yu Fan, Liangchang Li, Yang Sun
Discover Oncology.2025;[Epub] CrossRef - Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
Kelvin KH. Bao, Jeffrey CH. Chan, Jocelyn G. Chan, Leone Sutanto, Ka Man Cheung, Harry HY. Yiu
The Breast.2024; 73: 103612. CrossRef - Bilateral inflammatory recurrence of HER-2 positive breast cancer: a unique case report and literature review
Rong Qin, Xiangyang Wang, Tingting Fan, Ting Wu, Chao Lu, Xun Shao, Liang Yin
Frontiers in Oncology.2024;[Epub] CrossRef - Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation
Muhammad Javed Iqbal, Zeeshan Javed, Jesús Herrera-Bravo, Haleema Sadia, Faiza Anum, Shahid Raza, Arifa Tahir, Muhammad Naeem Shahwani, Javad Sharifi-Rad, Daniela Calina, William C. Cho
Cancer Cell International.2022;[Epub] CrossRef
- Trastuzumab deruxtecan: Redefining precision oncology across HER2-driven cancers
- 13,744 View
- 393 Download
- 10 Web of Science
- 9 Crossref
First
Prev
